Based on the information available, here's a breakdown of HMPV in India:
Impact in India:
- HMPV is a recognized respiratory pathogen in India.
- It contributes to respiratory tract infections, particularly in infants and young children.
- While it has been present for a long time, there are times of increased reporting, causing concern.
- Health officials are emphasizing that while it is something to be aware of, in most cases it causes mild illness.
- It is important to note that those with weakened immune systems can suffer from more severe complications.
Outbreak Time: - Respiratory viruses, including HMPV, tend to circulate more during the winter months.
- Therefore, increases in HMPV cases are often observed during these periods.
Affected Age: - HMPV can affect individuals of all ages.
- However, infants, young children, older adults, and individuals with weakened immune systems are at higher risk for severe infections.
Symptoms: - Common symptoms include:
- Fever
- Cough
- Runny or stuffy nose
- Sore throat
- Wheezing
- Difficulty breathing
- fatigue
- In severe cases, it can lead to bronchitis or pneumonia.
Clinical and Laboratory Diagnosis: - Diagnosis typically involves laboratory testing of respiratory samples (e.g., nasal swabs) using techniques like RT-PCR.
Treatment: - There is no specific antiviral treatment for HMPV.
- Treatment focuses on supportive care, such as:
- Managing fever
- Providing fluids
- Relieving respiratory symptoms
- In severe cases, hospitalization may be required.
- Antibiotics are not effective against viruses.
Prevention: - General preventive measures include:
- Frequent handwashing
- Covering coughs and sneezes
- Avoiding close contact with sick individuals
Vaccination:
- Currently, there is no widely available vaccine for HMPV.
Key points to remember: - HMPV is a common respiratory virus.
- Most infections are mild.
- Vulnerable populations are at higher risk for severe illness.
- Health officials are monitoring the situation.
đđđđđ - While most HMPV infections result in mild, cold-like symptoms, complications can arise, especially in vulnerable populations. Here's a breakdown of potential complications:
Lower Respiratory Tract Infections:
Pneumonia: HMPV can cause inflammation and fluid buildup in the lungs, leading to pneumonia. This is a serious complication that may require hospitalization.
Bronchiolitis: Particularly in infants and young children, HMPV can cause bronchiolitis, an inflammation of the small airways in the lungs. This can cause significant breathing difficulties and wheezing.
Bronchitis: Inflammation of the bronchial tubes.
Exacerbation of Existing Conditions:
HMPV can worsen pre-existing respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD). This can lead to increased symptoms and the need for additional medical intervention.
Secondary Bacterial Infections:
A weakened immune system due to HMPV infection can increase the risk of developing secondary bacterial infections, such as bacterial pneumonia.
Acute Respiratory Distress Syndrome (ARDS):
In very severe cases, HMPV can contribute to ARDS, a life-threatening lung condition.
Hospitalization:
Due to the above complications, hospitalization may be necessary, especially for infants, the elderly, and those with compromised immune systems. Key factors that increase the risk of complications include:
Young age (especially infants)
Older age
Weakened immune system
Pre-existing respiratory conditions It's important to seek medical attention if you or someone you know experiences severe respiratory symptoms, such as difficulty breathing or persistent wheezing. Translate in Bengali
â¨đâ¨đâ¨
ATTACK RATE
Currently, there is a lack of specific data comparing the attack rates of Human Metapneumovirus (HMPV) across metropolitan, urban, town, and village settings in India. Existing studies primarily focus on hospital-based data from urban centers. For instance, research conducted at the All India Institute of Medical Sciences in Delhi identified HMPV in 12% of children under five presenting with acute respiratory infections . Another study from a tertiary care center in Puducherry reported a 5% prevalence of HMPV among patients with influenza-like illness .
Due to the absence of comprehensive, community-based surveillance data encompassing various geographic settings, it's challenging to accurately compare HMPV attack rates between metropolitan, urban, town, and village populations. Implementing widespread surveillance across diverse regions is essential to gain a clearer understanding of HMPV's epidemiology in different community settings.
đâ¨đâ¨đâ¨
Area of HMPV that causes diseases
and used to detect.
Infecting and Diagnosed Parts of HMPV
1. Infecting Parts of HMPV:
HMPV primarily infects the respiratory system, particularly the lower respiratory tract. The key viral components responsible for infection include:
Glycoprotein (G protein):
Helps the virus attach to host cells in the respiratory tract.
Plays a major role in initial infection by binding to receptors on epithelial cells.
Fusion Protein (F protein):
Facilitates viral entry by fusing the viral envelope with the host cell membrane.
Helps the virus spread from cell to cell.
RNA Genome:
Contains the genetic material needed for viral replication inside host cells.
2. Diagnosed Parts of HMPV:
Diagnosis of HMPV is based on detecting the virus in respiratory secretions. The main diagnostic methods target:
Nasal or Throat Swabs:
Collected from the nasopharynx or oropharynx (upper respiratory tract).
Used for detecting viral RNA or antigens.
Respiratory Samples (e.g., Bronchoalveolar Lavage in Severe Cases):
Collected from the lungs in hospitalized patients.
Used in severe cases requiring intensive testing.
Diagnostic Tests:
RT-PCR (Reverse Transcription Polymerase Chain Reaction): Detects HMPV RNA in respiratory samples.
Immunofluorescence & ELISA: Detects viral proteins (antigens) in samples.
Summary:
Infecting parts: Virus attaches to and enters epithelial cells of the respiratory tract using G and F proteins.
Diagnosed parts: Virus is detected in nasal/throat swabs or lower respiratory samples using RT-PCR or antigen tests.
Acknowledgement: AI
Dr Rajatsubhra Mukhopadhyay.
